Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05489237 · ClinicalTrials.gov registry record · Phase 1
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
A Phase 1 study of Metastatic Cancer and Gastrointestinal Diseases, sponsored by IDRx Inc. - A GSK Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 278
- Enrollment target
- 20
- Study locations
NCT05489237: Recruiting Phase 1 study of Metastatic Cancer and Gastrointestinal Diseases, sponsored by IDRx Inc. - A GSK Company.
NCT05489237 is a Phase 1 study of Metastatic Cancer and Gastrointestinal Diseases that is actively recruiting participants, run by IDRx Inc. - A GSK Company. The registered enrollment target is 278 participants, below the 441-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (37% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05489237, a Phase 1 study of Metastatic Cancer and Gastrointestinal Diseases, is actively recruiting participants, sponsored by IDRx Inc. - A GSK Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 278 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is the first clinical trial of IDRX-42. The study is designed to evaluate the safety, tolerability, PK, and preliminary antitumor activity of IDRX-42 in adult participants with advanced (metastatic and/or surgically unresectable) GIST.
Conditions Studied
Interventions
- DRUG IDRX-42
Study Locations (20)
Other
- GSK Investigational Site - Leuven
- GSK Investigational Site - Beijing
- GSK Investigational Site - Guangzhou
- GSK Investigational Site - Wuhan
- GSK Investigational Site - Bordeaux
- GSK Investigational Site - Lyon
- GSK Investigational Site - Marseille
- GSK Investigational Site - Villejuif
- GSK Investigational Site - Berlin
- GSK Investigational Site - Essen
- GSK Investigational Site - Milan
- GSK Investigational Site - Chiba
- GSK Investigational Site - Tokyo
Florida
- GSK Investigational Site - Miami
Massachusetts
- GSK Investigational Site - Boston
Missouri
- GSK Investigational Site - St Louis
New York
- GSK Investigational Site - New York
Oregon
- GSK Investigational Site - Portland
Pennsylvania
- GSK Investigational Site - Philadelphia
Texas
- GSK Investigational Site - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 278 participants |
| Start Date | 2022-08-03 |
| Est. Completion | 2027-11-03 |
| Phase | Phase 1 |
What NCT05489237 shows while recruiting
NCT05489237 is an interventional study that assigns participants to a tested intervention. The registered 278 participants enrollment target is mid-sized for trials with a published cap, below the 441-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (37% lower).
The record links to 5 conditions, with Metastatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which IDRX-42 is the first listed.
NCT05489237 names 20 study sites across 8 states, led by Other, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05489237 about?
NCT05489237 is a clinical study titled "First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors". This is the first clinical trial of IDRX-42. The study is designed to evaluate the safety, tolerability, PK, and preliminary antitumor activity of IDRX-42 in adult participants with advanced (metastatic and/or surgically unresectable) GIST.
What is the current status of trial NCT05489237?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 278 participants. The study started on 2022-08-03. Estimated completion is 2027-11-03.
What conditions does trial NCT05489237 study?
This clinical trial studies the following conditions: Metastatic Cancer, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease.
What interventions are being tested in trial NCT05489237?
The interventions under investigation include: IDRX-42 (DRUG).
Who is sponsoring clinical trial NCT05489237?
This trial is sponsored by IDRx Inc. - A GSK Company, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05489237 being conducted?
This trial has 20 study locations across Florida, Massachusetts, Missouri, New York, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05489237's enrollment target sits among peer trials
278 18th of 109 higher than 92 of 109 other Metastatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
RECRUITING · Phase 1
-
Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer
RECRUITING · Phase 1
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04586959 · 278 participants · NA
Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
- NCT05010148 · 278 participants · Phase 3
A Clinical Trial of Intravenous Lidocaine After Spinal Surgery to Prevent Delirium and Reduce Pain
- NCT05965245 · 278 participants · NA
Suubi-Mhealth: A Mobile Health Intervention to Address Depression Among Youth
- NCT06188585 · 278 participants · NA
Randomized Trial of UI-EWD vs. Conventional Endoscopic Therapy for Nonvariceal Upper Gastrointestinal Bleeding
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI